Cardiac Abnormalities in HLH: Evaluation and Management
In HLH patients with cardiac abnormalities, immediately perform transthoracic echocardiography to assess ventricular function and initiate aggressive immunosuppression with corticosteroids (dexamethasone 10 mg/m² or methylprednisolone) alongside cardiovascular support, as cardiac involvement represents severe HLH with imminent organ failure requiring urgent etoposide-based therapy.
Recognition of Cardiac Involvement
Cardiac abnormalities in HLH can manifest as:
- Acute reversible cardiomyopathy with severe bi-ventricular failure
- Sudden cardiac arrest (rare but documented)
- Hemodynamic compromise with chest pain
- Torrential valvular regurgitation
The cardiac dysfunction is driven by the cytokine storm and represents a critical manifestation requiring immediate intervention 1, 2.
Immediate Evaluation
Perform serial transthoracic echocardiography to:
- Quantify ejection fraction and ventricular function
- Assess valvular competence
- Guide therapeutic response
Monitor cardiac biomarkers (troponin, BNP) alongside standard HLH parameters to track disease activity and treatment response 1.
Treatment Algorithm
1. Cardiovascular Support (Immediate)
For patients with hemodynamic compromise:
- Inotropic support: Levosimendan, milrinone
- Vasodilators: Glyceryl trinitrate as needed
- ICU-level monitoring with continuous hemodynamic assessment 1
2. Immunosuppression (Do Not Delay)
Severe HLH with organ failure (including cardiac) requires immediate etoposide:
- The 2019 Blood guidelines explicitly state: "A clear indication for immediate administration of etoposide is severe HLH presenting with imminent organ failure" 3
- Cardiac dysfunction qualifies as imminent organ failure
Initial regimen:
- Dexamethasone 10 mg/m² (or IV methylprednisolone if dexamethasone unavailable)
- Etoposide 150 mg/m² weekly (reduce to 50-100 mg/m² in elderly or those with comorbidities; adjust for renal impairment) 3
- IVIG 1.6 g/kg over 2-3 days (anti-inflammatory potential) 3
Additional agents based on severity:
- Anakinra (IL-1 inhibition) - particularly valuable in autoimmune-associated HLH 3, 4
- Rituximab if EBV-associated or lymphoma-triggered 1
- Cyclosporine A - consider early addition in severe cases 3
3. Weekly Reassessment
The graded intensity approach is critical 3:
- Perform echocardiography weekly to document cardiac recovery
- Adjust etoposide duration based on response (many require 8 weeks)
- Monitor for treatment toxicity while maintaining disease control
Key Clinical Pitfalls
Do not delay etoposide in cardiac HLH: The guidelines are explicit that organ failure mandates immediate etoposide, yet clinicians often hesitate due to concerns about cardiotoxicity. The cytokine storm itself is more immediately life-threatening than etoposide's potential cardiac effects 3.
Cardiac dysfunction is reversible with prompt treatment: The 2025 case report demonstrates complete normalization of ejection fraction from 18% to normal with aggressive immunosuppression 1. Delayed treatment risks irreversible multiorgan dysfunction.
Distinguish from primary cardiac pathology: In malignancy-associated HLH with cardiac masses, chemotherapy takes precedence over cardiac surgery 5. The hyperinflammation drives the cardiac dysfunction, not mechanical obstruction alone.
Etoposide Dosing Considerations
Adults with cardiac involvement require careful dosing:
- Standard: 150 mg/m² weekly
- Reduced: 50-100 mg/m² weekly if elderly or significant comorbidities 3
- Renal adjustment mandatory (etoposide is renally cleared)
- No dose reduction needed for isolated liver dysfunction 3
- Keep cumulative dose <2-3 g/m² in non-malignant HLH 3
Prognosis
Cardiac recovery parallels HLH control: Serial echocardiography showing improving ejection fraction indicates adequate immunosuppression 1. Persistent cardiac dysfunction despite treatment suggests either inadequate HLH control or need for treatment escalation to second-line agents (ruxolitinib, emapalumab) 4, 6.
The multidisciplinary approach combining cardiology support with aggressive immunosuppression enables full cardiac recovery in most cases when initiated promptly 1.